Aclaris Therapeutics, Inc.

“In 2016, we acquired additional intellectual property rights for the development and commercialization of certain JAK inhibitors for specified dermatological conditions.”

“In August 2017, we entered into an Agreement and Plan of Merger with Confluence ... resulting in our acquisition of 100% of the outstanding shares of Confluence.”

“We intend to continue to in-license or acquire additional drug candidates and technologies to build a fully integrated dermatology company.”

“In 2017, we acquired Confluence Life Sciences, Inc. (now known as Aclaris Life Sciences, Inc.), or Confluence. The acquisition of Confluence added small molecule drug discovery and preclinical development capabilities that allowed us to bring early-stage research and development activities in-house that we previously outsourced to third parties. We also earn revenue from Confluence’s provision of contract research services to third parties. We intend to leverage our proprietary drug discovery platform acquired from Confluence, called KINect, to identify potential drug candidates that we may develop independently or in collaboration with third parties. We also acquired several preclinical drug candidates, including inhibitors of the mitogen-activated protein kinase-activated protein kinase 2, or MK2, signaling pathway, topical Janus kinase, or JAK, inhibitors known as soft-JAK inhibitors, and inhibitors of interleukin-2-inducible T cell kinase, or ITK.”